FrancophonIA/ELRC3.0 huggingface dataset:
English: ANTACIDS Antacids (e.g., aluminium or magnesium hydroxide, calcium carbonate)
Slovenian: ANTACIDI antacidi (na primer aluminijev ali magnezijev hidroksid, kalcijev karbonat)
English: Warnings and precautions Talk to your doctor or pharmacist before taking EDURANT.
Slovenian: Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila EDURANT se posvetujte z zdravnikom ali farmacevtom.
English: Resistance to emtricitabine/lamivudine % (n/N)
Slovenian: Zdravljeni z efavirenzom odpornost na emtricitabin/lamivudin % (n/N) odpornost na efavirenz % (n/N)
English: Rilpivirine inhibits P-glycoprotein in vitro (IC50 is 9.2 μM).
Slovenian: In vitro rilpivirin zavira P-glikoprotein (IC50 9,2 mol/l).
English: This interaction study has been performed with a dose higher than the recommended dose for rilpivirine.
Slovenian: V tej interakcijski študiji so uporabljali večji odmerek rilpivirina od priporočenega.
English: Significant decreases in rilpivirine plasma concentrations are expected.
Slovenian: Pričakovano je pomembno zmanjšanje plazemskih koncentracij rilpivirina.
English: No dose adjustment of EDURANT is required in older patients (see section 5.2).
Slovenian: Prilagajanje odmerkov zdravila EDURANT pri starejših bolnikih ni potrebno (glejte poglavje 5.2).
English: The safety assessment is based on the week 48 analysis of the single-arm, open-label, Phase II trial, TMC278-C213, in which 36 antiretroviral treatment-naïve HIV-1 infected adolescent patients weighing at least 32 kg received rilpivirine (25 mg once daily) in combination with other antiretroviral agents (see section 5.1).
Slovenian: Ocena varnosti temelji na 48 tedenski analizi v odprti študiji faze II z eno preiskovano skupino, TMC278-C213, v kateri je 36 s HIV-1 okuženih mladostnikov, ki še niso prejemali protiretrovirusnih zdravil in s telesno maso najmanj 32 kg, prejemalo rilpivirin (25 mg enkrat na dan) v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavje 5.1).
English: The exposures at the embryo-foetal No Observed Adverse Effects Levels (NOAELs) in rats and rabbits were respectively 15 and 70 times higher than the exposure in humans at the recommended dose of 25 mg once daily.
Slovenian: Izpostavljenosti, pri katerih niso opažali nobenega vpliva na zarodek oziroma plod (No Observed Adverse Effects Levels, NOAEL), so bile pri podganah 15-krat, pri kuncih pa 70-krat večje od izpostavljenosti pri ljudeh po odmerjanju priporočenega odmerka 25 mg enkrat na dan.
English: If you take an H2-receptor antagonist (medicines used to treat stomach or intestinal ulcers or used to relieve heartburn due to acid reflux (such as cimetidine, famotidine, nizatidine or ranitidine).
Slovenian: Če jemljete antagoniste histaminskih receptorjev H2 (zdravila, ki jih uporabljamo pri zdravljenju razjed v želodcu ali črevesju ali za lajšanje zgage zaradi kislega refluksa, mednje sodijo cimetidin, famotidin, nizatidin in ranitidin).
English: When rifabutin co-administration is stopped, the EDURANT dose should be decreased to 25 mg once daily (see section 4.5).
Slovenian: Po prenehanju sočasnega jemanja rifabutina je treba odmerek zdravila EDURANT zmanjšati na 25 mg enkrat na dan (glejte poglavje 4.5).
English: In a study of healthy subjects, supratherapeutic doses of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QTc interval of the ECG (see section 5.1).
Slovenian: V študiji z zdravimi preiskovanci se je pokazalo, da so odmerki rilpivirina, ki so presegali terapevtski okvir, (75 mg enkrat na dan in 300 mg enkrat na dan) podaljšali interval QTc na EKG (glejte poglavje 5.1).
English: 400 mg once daily ketoconazole AUC ↓ 24% ketoconazole Cmin ↓ 66% ketoconazole Cmax ↔
Slovenian: 400 mg enkrat na dan ketokonazol AUC ↓ 24% ketokonazol Cmin ↓ 66% ketokonazol Cmax ↔
English: For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) taken once daily.
Slovenian: Pri bolnikih, ki sočasno jemljejo rifabutin je treba odmerek zdravila EDURANT zvečati na 50 mg (dve 25 mg tableti) enkrat na dan.
English: Take the antacid either at least 2 hours before or at least 4 hours after EDURANT (see section 2 “Other medicines and EDURANT”).
Slovenian: Antacid vzemite najmanj 2 uri pred zaužitjem zdravila EDURANT ali pa najmanj 4 ure po zaužitju zdravila EDURANT (glejte poglavje 2 “Druga zdravilo in zdravilo EDURANT”).
English: EDURANT should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes.
Slovenian: Zdravilo EDURANT je treba uporabljati previdno pri sočasni uporabi z učinkovinami, za katere je znano, da povečujejo tveganje za torsade de pointes.
English: Pregnant women should discuss the use of EDURANT with their doctor.
Slovenian: Nosečnice se morajo pred uporabo zdravila EDURANT posvetovati z zdravnikom.
English: Steady-state administration of rilpivirine 75 mg once daily and 300 mg once daily resulted in a mean Cmax approximately 2.6-fold and 6.7-fold, respectively, higher than the mean steady-state Cmax observed with the recommended 25 mg once daily dose of rilpivirine.
Slovenian: V stanju dinamičnega ravnovesja je pri odmerkih 75 mg rilpivirina enkrat na dan oziroma 300 mg enkrat na dan prišlo do večjih vrednosti povprečne Cmax, in sicer do približno 2,6-krat oziroma 6,7-krat višje vrednosti od povprečne Cmax v stanju dinamičnega ravnovesja pri priporočenem odmerku 25 mg rilpivirina enkrat na dan.
English: The pharmacokinetics, safety, tolerability and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, was evaluated in trial TMC278-C213, a single-arm, open-label Phase II trial in antiretroviral treatment-naïve HIV-1 infected adolescent subjects weighing at least 32 kg.
Slovenian: Farmakokinetiko, varnost, prenosljivost in učinkovitost zdravljenja s 25 mg rilpivirina enkrat na dan, v kombinaciji z BR po izboru raziskovalca, ki je vsebovala 2 NRTI, so ocenili v odprti študiji faze II z eno preiskovano skupino TMC278-C213 pri zdravljenju mladostnikov, okuženih s HIV-1, ki še niso prejemali protiretrovirusnih zdravil in s telesno maso najmanj 32 kg.
English: If you take these medicines, please carefully read how to take them in section 3 “Instructions for proper use in adults and adolescents (12 to less than 18 years of age)”.
Slovenian: Če sočasno jemljete to zdravilo in zdravilo EDURANT, skrbno preberite kako jemati zdravilo EDURANT, opisano v poglavju 3 “Navodila za pravilno uporabo pri odraslih in mladostnikih (starih od 12 do manj kot 18 let)”.
English: General disorders and administration site conditions common fatigue
Slovenian: Splošne težave in spremembe na mestu aplikacije pogosti utrujenost
English: (induction of CYP3A enzymes)
Slovenian: (indukcija encimov CYP3A)
English: Table 7:
Slovenian: Preglednica 7:
English: Considering all of the available in vitro and in vivo data in treatment-naïve subjects, the following resistance-associated mutations, when present at baseline, may affect the activity of rilpivirine: K101E, K101P, E138A, E138G, E138K, E138R, E138Q, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I, and M230L.
Slovenian: Na podlagi vseh dostopnih in vitro in in vivo podatkov pri bolnikih, ki še niso prejemali protiretrovirusnih zdravil bi naslednje mutacije, povezane z odpornostjo, lahko vplivale na aktivnost rilpivirina, če so prisotne že ob izhodišču: K101E, K101P, E138A, E138G, E138K, E138R, E138Q, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I, in M230L.
English: Take the H2-receptor antagonist at least 12 hours before or at least 4 hours after EDURANT (see section 2 “Other medicines and EDURANT”).
Slovenian: Antagonista histaminskih receptorjev H2 vzemite najmanj 12 ur pred zaužitjem zdravila EDURANT ali pa najmanj 4 ure po zaužitju zdravila EDURANT (glejte poglavje 2 “Druga zdravilo in zdravilo EDURANT”).
English: In the week 96 efficacy analysis, the virologic response rate [confirmed undetectable viral load (< 50 HIV-1 RNA copies/ml)] was evaluated in patients receiving rilpivirine 25 mg once daily in addition to a BR versus patients receiving efavirenz 600 mg once daily in addition to a BR.
Slovenian: Po 96 tednih zdravljenja so v analizi učinkovitosti ocenili delež bolnikov z virološkim odzivom [s potrjeno nezaznavno količino virusnega bremena (< 50 kopij RNK HIV-1/ml)] pri bolnikih, ki so prejemali 25 mg rilpivirina enkrat na dan poleg osnovne sheme zdravljenja, v primerjavi z bolniki, ki so prejemali efavirenz 600 mg enkrat na dan poleg osnovne sheme zdravljenja.
English: 6 cells/l).
Slovenian: 6 celic/l).
English: Human experience of overdose with rilpivirine is limited.
Slovenian: Izkušenj s prevelikim odmerjanjem rilpivirina pri ljudeh je malo.
English: In the open label part of the trial, patients originally randomised to one of the three doses of rilpivirine were all treated with rilpivirine 25 mg once daily in addition to a BR, once the dose for the Phase III studies was selected.
Slovenian: V odprtem delu študije, ko je bil odmerek za študije faze III že izbran, so vsi bolniki, ki so bili sprva randomizirani tako, da so prejemali enega od treh odmerkov rilpivirina, prejemali 25 mg rilpivirina enkrat na dan poleg zdravil po osnovni shemi.
English: Each film-coated tablet contains rilpivirine hydrochloride equivalent to 25 mg rilpivirine.
Slovenian: Ena filmsko obložena tableta vsebuje rilpivirinijev klorid v količini, ki ustreza 25 mg rilpivirina.
English: There is limited information regarding the use of EDURANT in patients > 65 years of age.
Slovenian: Pri bolnikih, starejših od 65 let, je o uporabi zdravila EDURANT na voljo malo podatkov.
English: simeprevir AUC ↔ simeprevir Cmin ↔ simeprevir Cmax ↑ 10% rilpivirine AUC ↔ rilpivirine Cmin ↑ 25% rilpivirine Cmax ↔
Slovenian: simeprevir AUC ↔ simeprevir Cmin ↔ simeprevir Cmax ↑ 10% rilpivirin AUC ↔ rilpivirin Cmin ↑ 25% rilpivirin Cmax ↔
English: Since rilpivirine is highly bound to plasma protein, dialysis is unlikely to result in significant removal of the active substance.
Slovenian: Ker se rilpivirin v velikem obsegu veže na proteine v plazmi, ga z dializo ni mogoče odstraniti v večji meri.
English: The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily.
Slovenian: Priporočilo za odmerjanje se nanašna na priporočeni odmerek 25 mg rilpivirina enkrat na dan.
English: Doing so could increase the risk of the virus developing resistance.
Slovenian: Če bi zdravljenje prekinili, bi zvečali možnost, da virus postane odporen na zdravila.
English: Other NRTIs (abacavir, emtricitabine, lamivudine, stavudine and zidovudine)
Slovenian: drugi nukleozidni zaviralci reverzne transkriptaze (NRTI) (abakavir, emtricitabin, lamivudin, stavudin in zidovudin)
English: Not studied.
Slovenian: Medsebojnega delovanja niso preučevali.
English: In this analysis, the resistance-associated mutations (RAMs) associated with NNRTI resistance that developed in at least 2 rilpivirine virologic failures were: V90I, K101E, E138K, E138Q, V179I, Y181C, V189I, H221Y, and F227C.
Slovenian: V tej analizi opažene mutacije (RAMs- resistance-assiciated mutations), povezane z odpornostjo na NNRTI, ki so se pojavile pri vsaj 2 neuspešnih viroloških zdravljenjih z rilpivirinom, so bile: V90I, K101E, E138K, E138Q, V179I, Y181C, V189I, H221Y in F227C.
English: Concomitant use of rilpivirine with ritonavir-boosted PIs causes an increase in the plasma concentrations of rilpivirine, but no dose adjustment is required.
Slovenian: Pri sočasni uporabi rilpivirina in PI, okrepljenih z ritonavirjem lahko pride do zvečanja plazemske koncentracije rilpivirina, vendar prilagajanje odmerkov ni potrebno.
English: If a patient vomits within 4 hours of taking the medicine, another EDURANT tablet should be taken with a meal.
Slovenian: Če bolnik v obdobju 4 ur po tem, ko je vzel zdravilo bruha, naj vzame še eno tableto zdravila EDURANT z obrokom.
English: The response rate (confirmed undetectable viral load < 50 HIV-1 RNA copies/ml) at week 96 was comparable between the rilpivirine arm and the efavirenz arm.
Slovenian: Stopnja odziva (potrjeno nezaznavno virusno breme < 50 HIV-1 kopij RNK HIV-1/ml) po 96 tednih zdravljenja je bila pri skupini, zdravljeni z rilpivirinom in skupini, zdravljeni z efavirenzom, primerljiva.
English: Repeated dose toxicity
Slovenian: Toksičnost večkratnih odmerkov
English: Subjects achieved virologic response (two consecutive viral loads < 50 copies/ml) and maintained it through week 48 and week 240.
Slovenian: Preiskovanci, pri katerih je prišlo do virološkega odziva (dvakrat zaporedoma izmerjeno virusno breme < 50 kopij/ml), ki se je ohranil do 48. in 240. tedna.
English: Pregnancy and Postpartum
Slovenian: Nosečnost in obdobje po porodu
English: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Slovenian: Preglednica 1: MEDSEBOJNA DELOVANJA Z DRUGIMI ZDRAVILI IN PRIPOROČILA ZA ODMERJANJE
English: If you notice after 12 hours, then skip that dose and take the next doses as usual.
Slovenian: Če se na pozabljeni odmerek spomnite po več kot 12 urah, izpustite ta odmerek in vzemite naslednji odmerek kot običajno.
English: The effects of EDURANT or other medicines might be influenced if you take EDURANT together with any of the following medicines.
Slovenian: Jemanje zdravila EDURANT lahko vpliva na druga zdravila ali pa druga zdravila vplivajo na zdravilo EDURANT, če jih jemljete sočasno.
English: The list of rilpivirine resistance-associated mutations presented in section 5.1 should only guide the use of EDURANT in the treatment-naïve population.
Slovenian: Preglednica mutacij, povezanih z odpornostjo na rilpivirin, v poglavju 5.1 se lahko uporablja samo kot smernica pri uporabi zdravila EDURANT pri populaciji, ki še ni bila zdravljena s protiretrovirusnimi zdravili.
English: EDURANT at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc.
Slovenian: Zdravilo EDURANT v priporočenem odmerku 25 mg enkrat na dan nima klinično pomembnega vpliva na interval QTc.
English: Immune system disorders uncommon immune reactivation syndrome
Slovenian: Bolezni imunskega sistema občasni sindrom obnove imunskega odgovora
English: In the pooled efficacy analysis from the Phase III trials in adults through 96 weeks, patients treated with rilpivirine with a baseline viral load > 100,000 HIV-1 RNA copies/ml had a greater risk of virologic failure (18.2% with rilpivirine versus 7.9% with efavirenz) compared to patients with a baseline viral load ≤ 100,000 HIV-1 RNA copies/ml (5.7% with rilpivirine versus 3.6% with efavirenz).
Slovenian: V analizi združenih podatkov o učinkovitosti iz preskušanj faze III pri odraslih bolnikih po 96 tednih, je bilo pri bolnikih z začetnim virusnim bremenom > 100.000 kopij RNK HIV-1/ml, ki so prejemali rilpivirin, tveganje za virološki neuspeh večje (18,2% v skupini, ki je jemala rilpivirin v primerjavi s 7,9% v skupini, ki je jemala efavirenz), kot pri bolnikih z začetnim virusnim bremenom ≤ 100.000 kopij RNK HIV-1/ml (5,7% v skupini, ki je jemala rilpivirin v primerjavi s 3,6% v skupini, ki je jemala efavirenz).
English: In mice, rilpivirine was positive for hepatocellular neoplasms in both males and females.
Slovenian: Pri miših je rilpivirin povzročal hepatocelularne neoplazme tako pri samcih kot pri samicah.
English: Virologic outcome in adult subjects in the ECHO and THRIVE trials (pooled data in the week 48 (primary) and week 96 analysis; ITT-TLOVR*) Outcome in the week 48 analysis
Slovenian: Preglednica 4: Virološki izid pri odraslih preiskovancih v študijah ECHO in THRIVE (združeni podatki po 48 (primarna) in 96 tednih analize zdravljenja; ITT-TLOVR Izid po 48 tednih zdravljenja
English: raltegravir AUC ↑ 9% raltegravir Cmin ↑ 27% raltegravir Cmax ↑ 10% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↔
Slovenian: raltegravir AUC ↑ 9% raltegravir Cmin ↑ 27% raltegravir Cmax ↑ 10% rilpivirin AUC ↔ rilpivirin Cmin ↔ rilpivirin Cmax ↔
English: Table 4 below shows the results of the week 48 and the week 96 efficacy analysis for patients treated with rilpivirine and patients treated with efavirenz from the pooled data from the ECHO and THRIVE trials.
Slovenian: V preglednici 4 so prikazani rezultati analize učinkovitosti po 48 in 96 tednih zdravljenja pri bolnikih, ki so prejemali rilpivirin, in pri bolnikih, ki so prejemali efavirenz, in sicer na podlagi podatkov, združenih iz študij ECHO in THRIVE.
English: Each tablet of EDURANT contains rilpivirine hydrochloride equivalent to 25 mg rilpivirine.
Slovenian: Ena tableta zdravila EDURANT vsebuje rilpivirinijev klorid v količini, ki ustreza 25 mg rilpivirina.
English: Liver toxicity associated with liver enzyme induction was observed in rodents.
Slovenian: Pri glodalcih so opazili toksičnost za jetra, ki je bila povezana z indukcijo jetrnih encimov.
English: All subjects with rilpivirine RAMs also had at least 1 treatment-emergent NRTI RAM at the last post-baseline time point with genotypic data.
Slovenian: Vsi preiskovanci z mutacijami, povezanimi z rezistenco na rilpivirin, so imeli tudi najmanj eno mutacijo zaradi zdravljenja z NRTI na zadnji točki po izhodišču z genotipskimi podatki.
English: It is not recommended to co-administer rilpivirine with other NNRTIs.
Slovenian: Sočasna uporaba rilpivirina z drugimi NNRTI ni priporočljiva.
English: However, it may not be excluded that the pharmacologically active, unbound, rilpivirine exposure is significantly increased in moderate hepatic impairment.
Slovenian: Možnosti, da je izpostavljenost farmakološko aktivnemu, nevezanemu rilpivirinu pri bolnikih z zmerno jetrno okvaro znatno povečana ni mogoče izključiti.
English: C-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively.
Slovenian: Po peroralnem odmerjanju enkratnega odmerka s C označenega rilpivirina je približno 85% radioaktivnosti mogoče prestreči v blatu, 6,1% pa v urinu.
English: Nervous system disorders very common headache dizziness common somnolence
Slovenian: Bolezni živčevja zelo pogosti glavobol omotica pogosti somnolenca
English: ANALGESICS Paracetamol* 500 mg single dose paracetamol AUC ↔ paracetamol Cmin NA paracetamol Cmax ↔ rilpivirine AUC ↔ rilpivirine Cmin ↑ 26% rilpivirine Cmax ↔
Slovenian: ANALGETIKI paracetamol* 500 mg enkraten odmerek paracetamol AUC ↔ paracetamol Cmin NS paracetamol Cmax ↔ rilpivirin AUC ↔ rilpivirin Cmin ↑ 26% rilpivirin Cmax ↔
English: In ECHO, randomisation was stratified by screening viral load.
Slovenian: V študiji ECHO je bila randomizacija stratificirana po količini virusnega bremena na začetnem pregledu za izbor preiskovancev (screening).
English: The ADRs are listed by system organ class (SOC) and frequency.
Slovenian: Neželeni učinki so razvrščeni po organskih sistemih in pogostnosti.
English: 40 mg once daily atorvastatin AUC ↔ atorvastatin Cmin ↓ 15% atorvastatin Cmax ↑ 35% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↓ 9%
Slovenian: 40 mg enkrat na dan atorvastatin AUC ↔ atorvastatin Cmin ↓ 15% atorvastatin Cmax ↑ 35% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↓ 9%
English: Of those patients who were responders at week 96, 74% of patients receiving rilpivirine remained with undetectable viral load (< 50 HIV-1 RNA copies/ml) at week 240 compared to 81% of patients receiving efavirenz.
Slovenian: Med bolniki z odzivom po 96 tednih zdravljenja z rilpivirinom je pri 74% virusno breme ostalo nezaznavno (< 50 kopij RNK HIV-1/ml) tudi po 240 tednih, v primerjavi z 81% bolnikov, ki so prejemali efavirenz.
English: EDURANT should be used with caution in this population.
Slovenian: Pri tej populaciji je pri uporabi zdravila EDURANT potrebna previdnost.
English: Table 2: ADRs reported in antiretroviral treatment-naïve HIV-1 infected adult patients treated with Rilpivirine (pooled data from the week 96 analysis of the Phase III ECHO and THRIVE trials) N=686 System Organ Class (SOC) Frequency Category ADRs (Rilpivirine + BR)
Slovenian: Preglednica 2: Neželeni učinki poročani pri odraslih bolnikih, okuženih s HIV-1, ki so bili zdravljeni z rilpivirinom in pred tem še niso prejemali protiretrovirusnih zdravil (analiza združenih podatkov po 96 tednih iz študij faze III ECHO in THRIVE) n=686 organski sistem kategorija pogostnosti neželeni učinki (rilpivirin + BR)
English: Therefore, EDURANT is not recommended in patients with severe hepatic impairment (see section 5.2).
Slovenian: Zato uporaba zdravila EDURANT pri bolnikih s hudo okvaro jeter ni priporočljiva (glejte poglavje 5.2).
English: rilpivirine AUC ↑ 16%* rilpivirine Cmin ↔* rilpivirine Cmax ↑ 43%*
Slovenian: rilpivirin AUC ↑ 16%* rilpivirin Cmin ↔* rilpivirin Cmax ↑ 43%*
English: In the rilpivirine arm in the week 96 analysis of the Phase III ECHO and THRIVE trials, mean change from baseline in total cholesterol (fasted) was 5 mg/dl, in HDL cholesterol (fasted) 4 mg/dl, in LDL cholesterol (fasted) 1 mg/dl, and in triglycerides (fasted) -7 mg/dl.
Slovenian: V analizi podatkov po 96 tednih zdravljenja z rilpivirinom v študijah faze III ECHO in THRIVE je bila povprečna sprememba koncentracije skupnega holesterola (na tešče) od izhodiščne vrednosti 50 mg/l, HDL holesterola (na tešče) 40 mg/l, LDL holesterola (na tešče) 10 mg/l in trigliceridov (na tešče)-70 mg/l.
English: rilpivirine AUC ↓ 42% rilpivirine Cmin ↓ 48% rilpivirine Cmax ↓ 31%
Slovenian: rilpivirin AUC ↓ 42% rilpivirin Cmin ↓ 48% rilpivirin Cmax ↓ 31%
English: 800/100 mg once daily darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔ rilpivirine AUC ↑ 130% rilpivirine Cmin ↑ 178% rilpivirine Cmax ↑ 79%
Slovenian: 800/100 mg enkrat na dan darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔ rilpivirin AUC ↑ 130% rilpivirin Cmin ↑ 178% rilpivirin Cmax ↑ 79%
English: EDURANT must be taken with a meal.
Slovenian: Zdravilo EDURANT je treba vzeti skupaj z obrokom.
English: The pharmacokinetic properties of rilpivirine have been evaluated in adult healthy subjects and in antiretroviral treatment-naïve HIV-1 infected patients 12 years of age and older.
Slovenian: Farmakokinetične lastnosti rilpivirina so ocenjevali pri zdravih odraslih osebah, okuženih s HIV-1, starih 12 let in več, ki še niso prejemali protiretrovirusnih zdravil.
English: Increase in CD4+ cell count (mean)
Slovenian: Povprečno povečanje št. celic CD4+
English: Gastrointestinal disorders very common nausea increased pancreatic amylase common abdominal pain vomiting increased lipase abdominal discomfort dry mouth
Slovenian: Bolezni prebavil zelo pogosti navzea zvečana koncentracija pankreasne amilaze pogosti bolečine v trebuhu bruhanje zvečana koncentracija lipaze neprijeten občutek v trebuhu suha usta
English: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions or aggravation of symptoms.
Slovenian: Pri bolnikih, okuženih s HIV, s hudo imunsko pomanjkljivostjo ob uvedbi kombinirane protiretrovirusne terapije (CART - Combination Antiretroviral Therapy), se lahko pojavi vnetna reakcija na asimptomatske ali prikrite oportunistične okužbe in povzroči resna klinična stanja ali poslabšanje simptomov.
English: Co-administration of rilpivirine and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine, which could reduce the therapeutic effect of rilpivirine.
Slovenian: Pri sočasni uporabi rilpivirina z učinkovinami, ki inducirajo CYP3A, so opazili zmanjšanje koncentracij rilpivirina v plazmi, kar lahko zmanjša terapevtski učinek rilpivirina.
English: The pharmacokinetics of rilpivirine in antiretroviral treatment-naïve HIV-1 infected adolescent subjects receiving EDURANT 25 mg once daily were comparable to those in treatment-naïve HIV-1 infected adults receiving EDURANT 25 mg once daily.
Slovenian: Farmakokinetika rilpivirina pri mladostnikih, okuženih s HIV-1, ki so prejemali zdravilo EDURANT 25 mg enkrat na dan in še niso bili zdravljeni s protiretrovirusnimi zdravili, je bila primerljiva farmakokinetiki pri odraslih bolnikih okuženih s HIV-1, ki so prejemali zdravilo EDURANT 25 mg enkrat na dan in se predhodno niso zdravili s protiretrovirusnimi zdravili.